Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study

ConclusionsAL 1064 mg q8wk provided continuous exposure to aripiprazole throughout the 8-week dosing interval and had a safety profile consistent with the 4- and 6-week regimens. These findings were used to support FDA approval of the 1064-mg dose administered every 2 months.RegistrationClinicaltrials.gov: NCT02320032

http://link.springer.com/10.1007/s40263-020-00745-1

Source: CNS Drugs - July 2, 2020 Category: Neurology Source Type: research